American Health Intel Rules. Money. Medicine. Decoded daily.
Subscribe
The Ledger · Tuesday, November 17, 2026

The Ledger

Rules. Money. Medicine. Decoded daily.
4 stories · 4 min read
Reading as

Minnesota cleared California-based Sutter Health’s takeover of Allina Health, and the price of approval is a $2.15 billion capital pledge over five years. The Minnesota Attorney General’s office says it reached a 10-year oversight agreement with Sutter and Allina, set out in a memorandum of understanding, according to the Minnesota Attorney General’s Sutter and Allina review page. The page lists the capital for finishing the Abbott Northwestern campus, information technology upgrades including rural sites, routine replacement and a new ambulatory network of surgery, urgent care and specialty hubs. It also holds trauma designations and core services at seven rural hospitals for five years, keeps existing union contracts, and requires annual reports to the attorney general, who keeps full authority to intervene if commitments are missed. The Minnesota Reformer dated the approval November 16 and reported a January closing; we could not open that article, and the AG page carries no announcement date or closing date. Who it hits: Minnesota employers and insurers negotiating with the state’s largest system, and every nonprofit board watching what an out-of-state buyer had to promise. So what: the guardrails are service and capital commitments plus reporting. The AG page lists no price cap, and the MOU itself was not retrieved this run. Confidence: High that the agreement exists and on the commitments listed on the AG page; Low to Med on the date and January closing.

Johnson & Johnson will pay $2.2 billion upfront for Ollin Biosciences, a developer of an eye-disease antibody now in Phase 3 trials. The company announced the deal November 16 in a Johnson & Johnson press release distributed through Business Wire. Milestone payments could add up to about $1.125 billion. Separately, Blackstone Life Sciences will pay J&J $750 million over several years to fully fund Phase 3 development of the lead drug, OLN324, in exchange for milestone payments and single-digit royalties, but only if the acquisition closes. OLN324 targets wet age-related macular degeneration and diabetic macular edema, which the release says affect more than 40 million people worldwide. Closing is expected before the end of 2026, pending regulatory approvals. Who it hits: retina specialists and ophthalmology practices that buy and administer eye injections, and the makers of competing injectables. So what: the buyer is paying up for a late-stage asset and has outside capital covering its trial cost. Confidence: High on the terms, which are in the company release. This is a drug-development deal, so the effect on care delivery is years away.

Medtronic agreed to buy Contego Medical, maker of a carotid artery stroke-prevention system, for about $380 million plus later payments. Medtronic announced the deal November 16 in a Medtronic press release. Contego’s Neuroguard system is described as the first and only FDA-approved system of its kind for transcarotid artery revascularization, a procedure that treats blockages in the neck artery. Medtronic has held exclusive U.S. distribution rights since January 2025, so this converts a distribution deal into ownership. It expects the deal to be minimally dilutive to adjusted earnings per share in fiscal 2027 and 2028, and to close in the third quarter of its fiscal year. Who it hits: vascular surgeons, hospital cath labs and value analysis committees that choose among carotid devices. So what: for hospitals, the supplier of a device they already buy now owns it outright. Confidence: Med to High on the terms; our read of the release was partial, so the $380 million figure should be checked against the full text.

Indiana’s Parkview Health completed its purchase of Ovation Healthcare, a shared-services company that sells revenue cycle and information services to rural hospitals in 48 states. Parkview announced the deal November 9, and Healthcare IT Today reported it as finalized in a November 16 roundup, supplemental trade source only. Parkview’s UpVia Health unit, launched in 2025, will combine with Ovation under the Ovation brand. No price was given in the article, and we did not read Parkview’s own release. Who it hits: independent rural hospitals that outsource back-office work to Ovation and now buy it from a health system. So what: a provider-owned back office is a new kind of competitor to vendor-owned revenue cycle firms. This completion is a week after the announcement, and we include it because we had not covered it. Confidence: Med on completion and structure; terms not disclosed.

A note on today’s scan: we checked insurer and hospital-operator filings, rating actions, closures, layoffs and deal announcements for the last 48 hours and found no earnings 8-Ks from the large insurers or hospital operators dated today and no health-system rating action we could verify. Surgery Partners posted no new development we could find after the amended $25 per share HealthSpan Partners deal. One report of a Michigan hospital bankruptcy and layoffs could not be dated, so it was left out. A frontier check of radiation oncology and proton therapy centers found no deal dated November 2026; the nearest was a June purchase of the Tennessee Oncology Proton Center by Remedy Medical Properties and Kayne Anderson Real Estate.

THE DEAL SHEET

TargetAcquirer/InvestorVerticalValueSource
Allina Health (Minnesota)Sutter HealthHealth system affiliation$2.15 billion capital commitment over 5 years; no purchase price listedMinnesota Attorney General
Ollin BiosciencesJohnson & JohnsonOphthalmology drug development$2.2 billion upfront plus up to about $1.125 billion in milestones (announced November 16)Johnson & Johnson release
Contego MedicalMedtronicVascular devicesAbout $380 million plus potential later payments (announced November 16)Medtronic release
Ovation HealthcareParkview HealthRural hospital shared servicesNot disclosed (announced November 9, completed)Healthcare IT Today
PursueCareXRHealthVirtual addiction treatmentNot disclosed (announced November 9)Healthcare IT Today
Independence Care Homecare NetworkDavion Healthcare (Nasdaq: DAVI)Home careTerms not confirmed; agreed to terms November 16 per company release headlineDavion GlobeNewswire release

Still pending from earlier this week: Surgery Partners and HealthSpan Partners, $25.00 per share cash, per the Surgery Partners 8-K exhibit.

Get tomorrow's edition in your inbox.

Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.

Where these stories are tracked
Get the next issue Free, daily